Peptain
Get the app

Enclomiphene

Also sold as Enclomid.

Half-life
10 h
Steady state
~2 d
Class
SERM
Category
TRT

Published population averages. Steady state is the usual five half-life rule of thumb, not a measurement. See peptide half-life, explained.

Overview

Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). Unlike racemic clomiphene (Clomid), which contains both zuclomiphene (estrogenic) and enclomiphene (anti-estrogenic) isomers, pure enclomiphene provides estrogen receptor antagonism without the accumulated estrogenic effects of zuclomiphene. It boosts endogenous testosterone by blocking hypothalamic estrogen feedback.

How it works

Selectively blocks estrogen receptors in the hypothalamus and pituitary, preventing estradiol-mediated negative feedback on GnRH and gonadotropin release. This increases LH and FSH secretion, driving endogenous testicular testosterone production and maintaining spermatogenesis. Unlike TRT, it enhances rather than replaces the HPG axis.

Half-life and peak

Oral half-life approximately 10 hours. Peak plasma levels reached 2–4 hours post-dose. Testosterone elevation typically observed within 1–2 weeks, with full effect at 4–6 weeks. Daily dosing at 12.5–25 mg.

What it is studied for

Secondary male hypogonadism, testosterone optimization without exogenous hormones, fertility preservation, alternative to TRT for mild hypogonadism.

Research status

Phase 3 trials completed (Androxal, Repros Therapeutics). FDA NDA submitted but received Complete Response Letter requesting additional data. Available through compounding pharmacies. Not yet FDA-approved as a standalone product.

Sources

Educational reference only. This page describes what is published about a compound; it is not medical advice, not a recommendation to take anything, and not a dosing guide. Several compounds in this catalog are investigational and are not approved medicines. Talk to a doctor.